Edition:
United Kingdom

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

6.60USD
23 Feb 2018
Change (% chg)

$0.40 (+6.45%)
Prev Close
$6.20
Open
$6.20
Day's High
$6.68
Day's Low
$6.15
Volume
114,644
Avg. Vol
114,211
52-wk High
$14.00
52-wk Low
$5.85

Latest Key Developments (Source: Significant Developments)

Aduro Biotech Announces Management Changes
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER.ADURO BIOTECH ANNOUNCES MANAGEMENT CHANGES.ADURO BIOTECH - GREGORY SCHAFER WILL BE STEPPING DOWN AS CHIEF OPERATING OFFICER IN EARLY MARCH.  Full Article

Aduro Biotech Provides Update On CRS-207 Programs
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH PROVIDES UPDATE ON CRS-207 PROGRAMS.COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207.COMPANY WILL WIND DOWN EACH OF ITS TRIALS IN MESOTHELIOMA, OVARIAN AND GASTRIC CANCER FOR CRS-207.EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO FUND PLANNED ACTIVITIES FOR NEXT THREE YEARS THROUGH 2020.  Full Article

Aduro Biotech reports Q3 loss per share $0.33
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Aduro Biotech Inc ::Aduro Biotech reports third quarter 2017 financial results.Q3 loss per share $0.33.Q3 revenue $3.8 million versus $3.8 million.Q3 revenue view $6.1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.Aduro Biotech Inc - ‍ anticipated 2017 milestones include to initiate phase 1 multiple myeloma trial with bion-1301, an anti-April antibody​.  Full Article

Aduro Biotech Q2 earnings per share view $0.06 -- Thomson Reuters I/B/E/S
Wednesday, 3 Aug 2016 

Aduro Biotech Inc : Aduro Biotech reports second quarter 2016 financial results . Q2 earnings per share $0.04 . Q2 revenue view $25.2 million -- Thomson Reuters I/B/E/S . Q2 revenue $39 million versus $9.9 million .Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Aduro Biotech announces phase 2b eclipse trial misses primary endpoint in heavily pretreated metastatic pancreatic cancer
Monday, 16 May 2016 

Aduro Biotech Inc : Phase 2b trial did not meet primary endpoint of improvement in overall survival for patients with pancreatic cancer who had failed at least 2 prior therapies in metastatic setting .Aduro Biotech announces phase 2b eclipse trial misses primary endpoint in heavily pretreated metastatic pancreatic cancer.  Full Article

BRIEF-Aduro Biotech Announces Management Changes

* ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER